Atara Biotherapeutics has appointed Kanya Rajangam chief medical officer. Before joining Atara (NASDAQ: [[ticker:ATRA]]), Rajangam was chief medical officer of Burlingame, CA-based Cleave Biosciences. Atara, based in South San Francisco, CA, expects to start two Phase 3 clinical trials later this year for its lead drug, ATA129, a potential treatment for certain lymphomas.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
